Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Bio-Rad PrimePCR Assays for Droplet Digital PCR

Premium

Bio-Rad Laboratories this week announced an expansion of its PrimePCR probe assays for Droplet Digital PCR, adding 56 assays for mutation detection and 109 assays for copy number variation analysis to the company's existing catalog for the QX100 and QX200 Droplet Digital PCR systems.

The new assays are the only ones available that are predesigned and fully wet-lab validated for digital PCR, Bio-Rad said. The assays are available in multiple reaction sizes with a FAM or HEX fluorophore, the company said.

The mutation detection assays include those for deletions in the anaplastic lymphoma kinase (ALK) gene, which are believed to be associated with acquired resistance to ALK tyrosine kinase inhibitor cancer therapy. The assays also target mutations associated with other cancers such as pancreatic cancer, melanoma, and lymphomas, Bio-Rad said. Many of the CNV assay targets are associated with cancers (leukemia, melanoma, and uveal melanoma) and neurological diseases.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.